Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Cancer Res. 2021 Sep 30;81(23):6018–6028. doi: 10.1158/0008-5472.CAN-21-0030

Figure 3. ENT treatment decreased cell viability and induced cell apoptosis via inhibition of SALL4.

Figure 3.

(A) Protein and (B) mRNA levels of SALL4 in H661 cells after the indicated treatment of ENT or DMSO control. (C) Pre-mRNA level of SALL4 in H661 cells after 48 hours treatment of ENT or DMSO control. (D) Cell viability of H661 cells after indicated treatment for 5 days. (E) Flow cytometry of H661 cells after indicated treatment. (F) Percent apoptotic and dead cells in (E). (G) Cell viability of ENT pre-treated H661 cells after transfection of negative control or SALL4 overexpression vector. (H) Flow cytometry of ENT pre-treated H661 cells after indicated treatment. (I) Percent apoptotic and dead cells in (H). *P<0.05, **P<0.01, ***P<0.001, N=3.